Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 5
2002 5
2003 7
2004 9
2005 12
2006 9
2007 10
2008 10
2009 3
2010 10
2011 4
2012 4
2013 6
2014 5
2015 3
2016 4
2017 1
2018 3
2019 4
2020 2
2021 5
2022 6
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Siegfried EC, et al. BMC Pediatr. 2016 Jun 7;16:75. doi: 10.1186/s12887-016-0607-9. BMC Pediatr. 2016. PMID: 27267134 Free PMC article. Review.
Topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, available for 1-2 decades, are not associated with atrophy or increased percutaneous absorption after prolonged use and have much lower potential for systemic effects. ...CONCLUSIONS:
Topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, available for 1-2 decades, are not associate
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
METHODS: A total of 2418 infants were enrolled in this 5-year open-label study. Infants were randomized to PIM (n = 1205; with short-term TCSs for disease flares) or TCSs (n = 1213). The primary objective was to compare safety; the secondary objective was to documen …
METHODS: A total of 2418 infants were enrolled in this 5-year open-label study. Infants were randomized to PIM (n = 1205; with short-term
Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis.
Caputo R, Marziali E, de Libero C, Di Grande L, Danti G, Virgili G, Villani E, Mori F, Bacci GM, Lucenteforte E, Pucci N. Caputo R, et al. Cornea. 2021 Nov 1;40(11):1395-1401. doi: 10.1097/ICO.0000000000002751. Cornea. 2021. PMID: 34029239
PURPOSE: The aim of this study was to evaluate the safety and efficacy of tacrolimus 0.1% eye drops in a large population of pediatric patients affected by a severe form of vernal keratoconjunctivitis (VKC) who responded poorly to cyclosporine eye drops. ...This stu …
PURPOSE: The aim of this study was to evaluate the safety and efficacy of tacrolimus 0.1% eye drops in a large population of p …
Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study.
Salava A, Perälä M, Pelkonen A, Mäkelä M, Remitz A. Salava A, et al. Clin Exp Dermatol. 2022 May;47(5):889-902. doi: 10.1111/ced.15024. Epub 2022 Jan 13. Clin Exp Dermatol. 2022. PMID: 34798685
BACKGROUND: Topical tacrolimus is used off-label in young children, but data are limited on its use in children under 2 years of age and for long-term treatment. AIM: To compare safety differences between topical tacrolimus (0.03% …
BACKGROUND: Topical tacrolimus is used off-label in young children, but data are limited on its use in children under 2 years …
Optimizing topical management of atopic dermatitis.
Butala S, Paller AS. Butala S, et al. Ann Allergy Asthma Immunol. 2022 May;128(5):488-504. doi: 10.1016/j.anai.2022.03.004. Epub 2022 Mar 12. Ann Allergy Asthma Immunol. 2022. PMID: 35288275 Review.
Topical nonsteroidal agents, calcineurin inhibitors, crisaborole, and recently, ruxolitinib, which cause no cutaneous atrophy, are options for reducing the use of topical corticosteroids, including on sensitive sites. ...Dupilumab, an interleukin-4 rec
Topical nonsteroidal agents, calcineurin inhibitors, crisaborole, and recently, ruxolitinib, which cause no cutaneous a
No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.
Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH. Paller AS, et al. J Am Acad Dermatol. 2020 Aug;83(2):375-381. doi: 10.1016/j.jaad.2020.03.075. Epub 2020 Apr 1. J Am Acad Dermatol. 2020. PMID: 32246968 Free article.
BACKGROUND: Long-term safety of topical calcineurin inhibitors is not well understood. ...CONCLUSION: The cancer incidence was as expected, given matched background data. This finding provides no support for the hypothesis that topical
BACKGROUND: Long-term safety of topical calcineurin inhibitors is not well understood. ...CONCLUSI …
Long-term safety of tacrolimus ointment in atopic dermatitis.
Remitz A, Reitamo S. Remitz A, et al. Expert Opin Drug Saf. 2009 Jul;8(4):501-6. doi: 10.1517/14740330902969441. Expert Opin Drug Saf. 2009. PMID: 19435404 Review.
Despite these findings, many physicians remain concerned about possible long-term malignancies associated with long-term treatment with a topical calcineurin inhibitor. OBJECTIVE: To identify in the published literature possible long
Despite these findings, many physicians remain concerned about possible long-term malignancies associated with long- …
Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients.
Koh K, Jun I, Kim TI, Kim EK, Seo KY. Koh K, et al. BMC Ophthalmol. 2021 Jun 5;21(1):247. doi: 10.1186/s12886-021-01998-0. BMC Ophthalmol. 2021. PMID: 34088281 Free PMC article.
BACKGROUND: No studies have been reported on the efficacy and safety of long-term (12 months) use of topical tacrolimus for refractory ocular surface inflammation in pediatric patients. ...During the follow-up period, all patients showed improve …
BACKGROUND: No studies have been reported on the efficacy and safety of long-term (12 months) use of topical
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T, Kapp A, Spergel J. Hultsch T, et al. Dermatology. 2005;211(2):174-87. doi: 10.1159/000086739. Dermatology. 2005. PMID: 16088174 Free article. Review.
The recently introduced topical calcineurin inhibitors pimecrolimus cream 1% (Elidel) and tacrolimus ointment 0.03 and 0.1% (Protopic) exhibit a more selective mechanism of action and do not affect Langerhans cells/dendritic cells. ...None of the to
The recently introduced topical calcineurin inhibitors pimecrolimus cream 1% (Elidel) and tacrolimus ointment 0. …
Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.
Spergel JM, Leung DY. Spergel JM, et al. Curr Allergy Asthma Rep. 2006 Jul;6(4):270-4. doi: 10.1007/s11882-006-0059-7. Curr Allergy Asthma Rep. 2006. PMID: 16822378 Review.
Topical calcineurin inhibitors (pimecrolimus, Elidel, East Hanover, NJ; and tacrolimus, Protopic, Tokyo, Japan) have been approved for the use in atopic dermatitis since the year 2000. These compounds represent a relatively safe class of topical
Topical calcineurin inhibitors (pimecrolimus, Elidel, East Hanover, NJ; and tacrolimus, Protopic, Tokyo, Japan)
123 results